This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts. CEO Paul Long elaborates on the company’s growth drivers, including new product sales in Australia and Europe, and outlines their strategy to maintain market share and expand in emerging European markets.
More From The Market Online
Market Close: ASX Ltd drops on ASIC $150M raise request; iron ore offsets gold bounceback
Good Afternoon and welcome to Market Close for Monday of Week 51, I’m Jon Davidson.
- Jonathon Davidson
- 2 mins
- 15 December 2025 14:51 (AEDT)
Monday’s HotCopper trends: Winsome, 4D Medical, and other daily topics | Dec 15
With more than seven million users on the HotCopper forums, every discussion and speculation can move Australian markets, which is why getting out in front
- Isaac McIntyre
- 2 mins
- 15 December 2025 13:58 (AEDT)
American Tungsten and Antimony leaves ‘Trigg’ name behind to start next era (and set fresh focus)
American Tungsten and Antimony has entered a new era, leaving the name "Trigg Minerals" behind to…
- Isaac McIntyre
- 2 mins
- 15 December 2025 13:38 (AEDT)
How to manage money on the average Aussie income
This week on Money and Investing, Mitch Olarenshaw and I break down how to manage money on the average Australian income, using practical
- Andrew Baxter
- 2 mins
- 15 December 2025 12:30 (AEDT)
